Abstract 2108P
Background
Vitamin B12 impairment is common in cancer patients due to several factors, namely gastrointestinal (GI) surgery, malnutrition, liver metastases, and chemotherapy. Data regarding their prevalence and significance in this setting, as well as the impact on the overall prognosis, are lacking.
Methods
We retrospectively enrolled patients hospitalized for various cancer-related conditions at our Medical Oncology ward (2017-2022). Plasma B12 levels were stratified as Very Low (VL <200 pg/ml), Low (L 200-300 pg/ml), Normal (N 300-813 pg/ml) or High (H >813 pg/ml). We collected demographic and clinical data, including BMI, Cumulative Illness Rating Scale, nutritional status, ECOG PS, primary cancer site, disease stage, liver involvement and function tests, GI surgery. Univariate and multivariate statistical tests identified variables statistically associated to vitamin B12 (p<0.05).
Results
We enrolled 788 patients (F/M: 1.05, median age: 72, IQR: 62-78 y), VL B12 levels were found in 14.09% cases, L in 19.42%, N in 49.37% and H in 17.13%. At univariate analysis, B12 distribution was significantly different between genders, with females being characterized by higher median values compared to males. Vitamin B12 distribution increased significantly as function of ECOG PS levels. Breast cancer patients were characterized by the highest median B12 value while colorectal cancer patients by the lowest. B12 was also significantly higher in advanced compared to early-stage patients as well as in those who had liver failure. The correlation between B12 and age, albumin, prealbumin, total protein and folates was statistically significant but negligible (|r|<0.3). Multivariate analysis showed that the probability of H vs VL B12 levels was increased in patients with hypoproteinemia, hypoprealbuminemia and ECOG PS≥2, and decreased in those with colorectal and gastric cancer
Conclusions
To our knowledge, this is the first study investigating B12 levels in a wide and well clinically-characterized group of cancer patients; our data suggest that increased B12 is associated to an impaired clinical status, while in early stage patients, especially the elderly, B12 deficiency is of concern and may negatively impact the overall outcomes.
Clinical trial identification
#2734CE, released on the 31/01/2023.
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Pavia - Istituti Clinici Scientifici Maugeri.
Funding
Has not received any funding.
Disclosure
A. Malovini: Financial Interests, Personal, Stocks/Shares: Biomeris S.R.L. L.D. Locati: Financial Interests, Institutional, Speaker, Consultant, Advisor: Lilly, Eisai, MSD, Ipsen, Bayer, Roche, Gentili SrL. All other authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06